Christopher McGraw

Dr. Christopher McGraw

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2020 in Epilepsy Research
Verified
Journal Article
Closed access
JSJason R. Smith
Jason R. Smith
FJFelipe J.S. Jones
Felipe J.S. Jones
BFBrandy E. Fureman
Brandy E. Fureman
JBJeffrey R. Buchhalter
Jeffrey R. Buchhalter
SHSusan T. Herman
Susan T. Herman
LMLidia M.V.R. Moura
Lidia M.V.R. Moura

26 January 2021 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
CMChristopher McGraw
Christopher McGraw
SMSonal Mahida
Sonal Mahida
PJParul Jayakar
Parul Jayakar
HKHyun Yong Koh
Hyun Yong Koh
ATAlan Taylor
Alan Taylor
APAnnapurna Poduri
Annapurna Poduri
We report two siblings with intractable epilepsy, developmental regression, and progressive cerebellar atrophy due to biallelic variants in the gene CAD. For the affected girl, uridine started at age 5 resulted in dramatic improvements in seizure control and development, cessation of cerebellar atrophy, and resolution of hematological abnormalities. Her older brother had a more severe course and only modest response to uridine started at 14 years old. Treatment of this progressive condition via uridine supplementation provides an example of precision diagnosis and treatment using clear outcome measures and biomarkers to monitor efficacy.


17 August 2022 in Epilepsy Research
Verified
Journal Article
Closed access
MFMarta Fernandes
Marta Fernandes
MDMaria A. Donahue
Maria A. Donahue
DHDan Hoch
Dan Hoch
SCSydney Cash
Sydney Cash
SZSahar Zafar
Sahar Zafar
LMLidia M.V.R. Moura
Lidia M.V.R. Moura

1 January 2024 in Therapeutic Advances in Rare Disease
Verified
Journal Article
Open access
SPStephanie Prince
Stephanie Prince
EBEmily Bonkowski
Emily Bonkowski
CMChristopher McGraw
Christopher McGraw
CSChristina SanInocencio
Christina SanInocencio
HMHeather C Mefford
Heather C Mefford
BBBrian Broadbent
Brian Broadbent
Coalition to Cure CHD2 (CCC) is a patient advocacy group dedicated to improving the lives of those affected by CHD2-related disorders (CHD2-RD) by increasing education, building community, and accelerating research to uncover a cure. CHD2 is a chromatin remodeler that was identified in 2013 as being a genetic cause for developmental and epileptic encephalopathies. Pathogenic changes in CHD2 can cause treatment-resistant epilepsy, intellectual and developmental delays, and autism, and some individuals experience neurodevelopmental regression. There are currently no targeted therapies available for CHD2-related disorders. Haploinsufficiency of CHD2 is a causative mechanism of disease for individuals with pathogenic variants (primarily truncating) in CHD2. Recently, identification of individuals with deletion of nearby gene CHASERR, a regulator of CHD2 gene expression, has established dosage sensitivity in CHD2 and solidified the CHASERR gene as a potential therapeutic target for CHD2 levels. Through collaboration with our community and our scientific advisory board, CCC has created a Roadmap to Cure CHD2 as our guide toward a targeted cure that can benefit our community, with steps including (1) identifying and defining patients, (2) developing models of CHD2, (3) studying models of CHD2, (4) testing therapies, (5) involving patients, and (6) reaching a cure. Despite some of the challenges inherent in CHD2 research including establishing animal and cellular models that recapitulate the CHD2 clinical phenotype, identifying measurable outcomes and reliable biomarkers, or testing emerging therapeutic approaches, CCC continues to engage with our community to support ongoing research that aligns with our priorities. CCC sees new and exciting opportunities for additional research that can move our community toward our common goal of a cure that will improve the lives of individuals and their families now and in the future.

8 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CLChristopher Mark LaCoursiere
Christopher Mark LaCoursiere
JUJeremy F.P. Ullmann
Jeremy F.P. Ullmann
HKHyun Yong Koh
Hyun Yong Koh
LTLaura Turner
Laura Turner
CBCristina M. Baker
Cristina M. Baker
APAnnapurna Poduri
Annapurna Poduri
Summary: Hundreds of novel candidate human epilepsy-associated genes have been identified thanks to advancements in next-generation sequencing and large genome-wide association studies, but establishing genetic etiology requires functional validation. We generated a list of >2200 candidate epilepsy-associated genes, of which 81 were determined suitable for the generation of loss-of-function zebrafish models via CRISPR/Cas9 gene editing. Of those 81 crispants, 48 were successfully established as stable mutant lines and assessed for seizure-like swim patterns in a primary F 2 screen. Evidence of seizure-like behavior was present in 5 ( arfgef1, kcnd2, kcnv1, ubr5, wnt8b ) of the 48 mutant lines assessed. Further characterization of those 5 lines provided evidence for epileptiform activity via electrophysiology in kcnd2 and wnt8b mutants. Additionally, arfgef1 and wnt8b mutants showed a decrease in the number of inhibitory interneurons in the optic tectum of larval animals. Furthermore, RNAseq revealed convergent transcriptional abnormalities between mutant lines, consistent with their developmental defects and hyperexcitable phenotypes. These zebrafish models provide strongest experimental evidence supporting the role of ARFGEF1, KCND2 , and WNT8B in human epilepsy and further demonstrate the utility of this model system for evaluating candidate human epilepsy genes. Highlights: Zebrafish models generated by CRISPR/Cas9 gene editing display seizure-like swim patterns in five candidate human epilepsy genes: arfgef1, kcnd2, kcnv1, ubr5, wnt8b . Local field potential abnormalities recorded from kcnd2 and wnt8b crispants provide additional evidence of hyperexcitability. Arfgef1 and wnt8b mutant larvae have fewer inhibitory interneurons than wild type in the optic tectum. CRISPR-generated mutants of epilepsy genes displayed convergent transcriptional dysregulation, consistent with developmental abnormalities and their hyperexcitability phenotype.